<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2845">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510493</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02008; me20Donath2</org_study_id>
    <nct_id>NCT04510493</nct_id>
  </id_info>
  <brief_title>Canakinumab in Patients With COVID-19 and Type 2 Diabetes</brief_title>
  <acronym>CanCovDia</acronym>
  <official_title>Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether Canakinumab has beneficial effects on
      patients with Type 2 diabetes mellitus and coronavirus disease 19 (COVID19).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a metabolic syndrome (overweight, diabetes, hypertension) have a particularly
      bad outcome if infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
      This may be explained by an over-activation of the Interleukin-1 (IL-1) beta system.
      Metabolic stress (increased glucose and lipid levels) induces NOD-, LRR- and pyrin
      domain-containing protein 3 (NLRP3) -mediated IL-1beta secretion. SARS-CoV2 also activates
      NLRP3. Therefore, the study proposes that metabolic stress in patients with overweight and
      diabetes potentiates COVID-19 induced hyperinflammatory syndrome leading to excess mortality
      in these vulnerable patients. Canakinumab (Ilaris®) is a recombinant, human monoclonal
      antibody antagonizing IL-1beta by blocking IL-1beta activity. The aim of the study is to
      investigate the effect of canakinumab in type 2 diabetic patients with COVID-19.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>unmatched win ratio after treatment with canakinumab compared to Placebo (composite endpoint)</measure>
    <time_frame>within 4 weeks after treatment with canakinumab or placebo</time_frame>
    <description>Treatment and placebo will be compared on the basis of the unmatched win-ratio approach of Pocock. When comparing two patients, the winner will be determined by the first component in which the two patients differ (4 weeks after randomization):
longer survival time
longer ventilation-free time
longer ICU-free time
shorter hospitalization time
If there is no difference between treatment and Placebo: the win ratio is 1. If there is a difference between treatment and Placebo: the win ratio is not 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>From randomization up to 4 weeks</time_frame>
    <description>Time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever comes first. &quot;The seven-category ordinal scale consists of the following categories:
not hospitalized with resumption of normal activities;
not hospitalized, but unable to resume normal activities;
hospitalized, not requiring supplemental oxygen;
hospitalized, requiring supplemental oxygen;
hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both;
hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and
death&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Death rate during the 4-week period after study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to intensive care unit (ICU)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Admission to the intensive care unit from the medical ward during the 4-week period after study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary worsening of disease</measure>
    <time_frame>4 weeks</time_frame>
    <description>Secondary worsening of disease (i.e., development of Acute respiratory distress Syndrome (ARDS), increase of oxygen demand after 72h of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged hospital stay</measure>
    <time_frame>&gt;3 weeks</time_frame>
    <description>Prolonged hospital stay &gt; 3 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio to baseline in the glycated hemoglobin</measure>
    <time_frame>Baseline, Day 29 and Day 90</time_frame>
    <description>Ratio to baseline in the glycated hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio to baseline in the fasting glucose</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Ratio to baseline in the fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio to baseline in the fasting insulin</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Ratio to baseline in the fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio to baseline in the fasting c-peptide</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Ratio to baseline in the fasting c-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio to baseline in the C-reactive protein (CRP)</measure>
    <time_frame>Baseline, Day 29 and Day 90</time_frame>
    <description>Ratio to baseline in the C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio to baseline in the D-dimer</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Ratio to baseline in the D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio to baseline in the Natriuretic peptide (NTproBNP)</measure>
    <time_frame>Baseline, Day 29 and Day 90</time_frame>
    <description>Ratio to baseline in the Natriuretic peptide (NTproBNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio to baseline in the Glomerular Filtration Rate Renal (eGFR)</measure>
    <time_frame>Baseline, Day 29 and Day 90</time_frame>
    <description>Ratio to baseline in the Glomerular Filtration Rate Renal (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of antidiabetic treatment at Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Type of antidiabetic treatment at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antidiabetic treatment at Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Number of antidiabetic treatment at Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of antidiabetic treatment at three months</measure>
    <time_frame>Month 3</time_frame>
    <description>Type of antidiabetic treatment at three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antidiabetic treatment at three months</measure>
    <time_frame>Month 3</time_frame>
    <description>Number of antidiabetic treatment at three months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Coronavirus Infection</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>active treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Canakinumab i.v. administered over 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo treatment arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <description>Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours</description>
    <arm_group_label>active treatment arm</arm_group_label>
    <other_name>Ilaris®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours</description>
    <arm_group_label>placebo treatment arm</arm_group_label>
    <other_name>Aqua ad injectabilia in 250 ml 5% dextrose solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes mellitus

          -  Body mass index &gt; 25 kg/m² (overweight)

          -  Hospitalized with COVID-19

        Exclusion Criteria:

          -  Suspected or known untreated active bacterial, fungal, viral, or parasitic infection
             with the exception of COVID-19

          -  Treatment with immunomodulators or immunosuppressant drugs, including but not limited
             to tocilizumab, tumor necrosis factor (TNF) inhibitors and anti-IL-17 agents within 5
             half-lives or 30 days (whichever is longer) prior to randomization with the exception
             of anakinra which is excluded within 5 half-lives only. Note: Immunomodulators
             (topical or inhaled) for asthma and atopic dermatitis, and corticosteroids (any route
             of administration) such as dexamethasone are permitted.

          -  History of hypersensitivity to canakinumab or to biologic drugs

          -  Neutrophil count &lt;1000/mm3

          -  Pregnant or nursing (lactating) women

          -  Participation in another study with investigational drug within the 30 days preceding
             and during the present study-
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Donath, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Donath, MD, Prof.</last_name>
    <phone>+41 61 265 5078.</phone>
    <email>marc.donath@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Mudry, MD</last_name>
    <phone>+41 61 328 58 53</phone>
    <email>jonathan.mudry@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Clinic Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Philipp Schütz, MD, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Beat Müller, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Donath, MD, Prof.</last_name>
      <phone>+41 61 265 5078</phone>
      <email>marc.donath@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Mudry, MD</last_name>
      <phone>+41 61 328 58 53</phone>
      <email>jonathan.mudry@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Donath, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Mudry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Hepprich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Battegay, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Hunziker, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Stettler, MD, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Markus Laimer, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Alain Golay, MD, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>François Jornayvaz, MD, PD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Nelly Pittteloud, MD, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Peter Kopp, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital Lucerne</name>
      <address>
        <city>Luzern</city>
        <zip>6004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Henzen, MD, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Fischli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Burget, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital St Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Brändle, MD, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Bilz, MD, PD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Felix Beuschlein, MD, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Roger Lehmann, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NLRP3</keyword>
  <keyword>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</keyword>
  <keyword>Coronavirus Disease 19 (COVID-19)</keyword>
  <keyword>IL-1beta</keyword>
  <keyword>hyperinflammatory syndrome</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

